

Other factors to consider

A group of doctors, nurses, and other medical staff (called the “study team”) will:

- explain the possible risks and benefits of the study
- monitor your health carefully
- provide you with the study medicine and study-related tests at no cost.

You will not be paid to participate in this study. You may be paid back (reimbursed) for reasonable time and travel costs.

An Institutional Review Board (IRB)/Ethics Committee (EC) protects the rights, safety, and well-being of study participants. An IRB/EC has reviewed this study.

The US Food and Drug Administration (FDA) approved vedolizumab in May 2014.



Who can take part?

People who **may** be able to take part must:


- be 18–80 years of age
- have moderate to severely active ulcerative colitis or Crohn’s disease
- have previously received at least 1 treatment that has not worked or stopped working over time.



Participating in a clinical study is an important decision. Please ask all the questions you have before deciding whether to take part. Study participation is voluntary. By contacting us, you do not have to take part in the study.

How do I get more information?

Please contact the study team.



Crohn’s and colitis study:
Could you help us understand more about the treatment landscape?



Study Information

A study for people with ulcerative colitis and Crohn’s disease



What is a clinical research study?

A clinical research study is a medical study that helps to answer important questions about an investigational or approved medicine, such as:

- Does it work?
- How safe is it?
- What are the possible risks and benefits?

We ask people to take part in these studies so we can find new medicines and new ways of taking them.

An Institutional Review Board (IRB)/Ethics Committee (EC) protects the rights, safety, and well-being of study participants. An IRB/EC has reviewed and approved the study materials.



Tell me more about vedolizumab

Vedolizumab was developed to prevent white blood cells from “invading” the bowel and causing inflammation.



People can receive vedolizumab as a first treatment option. It is often used when other conventional treatment do not work, stop working, or cause unwanted side effects.

About the PANORAMA Study

This study is looking at an approved medicine for the treatment of ulcerative colitis and Crohn’s disease called vedolizumab or Entyvio®.


We also want to learn more about your and other patients’ experiences of using vedolizumab in their community and how it:

- changes both short-term and long-term symptoms, and the severity of bowel inflammation
- changes the impact on the physical and mental health of people with ulcerative colitis or Crohn’s disease.


The information we gather may help us to learn more about vedolizumab and better understand how to treat ulcerative colitis and Crohn’s disease in the future.



Quick facts about the study



You will be in the study for about **72 weeks** (16 months).



You will first receive vedolizumab via a tiny drip inserted into your arm called an “**intravenous infusion**”.



After 2 or 3 infusions, you will learn to give yourself vedolizumab by an injection under the skin using a **prefilled pen**.



About **400** people in the United States will take part: **200** with ulcerative colitis and **200** with Crohn’s disease.